Misconstruing Single-Arm Study Data Lands BMS In Trouble With US FDA

 
• By Sarah Karlin-Smith
doctor that appears to be "holding" lungs
The BMS lung cancer drug was the subject of the FDA's third OPDP letter of the year. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance